Search Page

1

Cite

Share

A Pilot Study of Exenatide Actions in Alzheimer's Disease.

Mullins RJ, Mustapic M, Chia CW, Carlson O, Gulyani S, Tran J, Li Y, Mattson MP, Resnick S, Egan JM, Greig NH, Kapogiannis D. Mullins RJ, et al. Among authors: gulyani s. Curr Alzheimer Res. 2019;16(8):741-752. doi: 10.2174/1567205016666190913155950. Curr Alzheimer Res. 2019. PMID: 31518224 Free PMC article. Clinical Trial.

Cite

Share

2

Cite

Share

Utility of Neuronal-Derived Exosomes to Examine Molecular Mechanisms That Affect Motor Function in Patients With Parkinson Disease: A Secondary Analysis of the Exenatide-PD Trial.

Athauda D, Gulyani S, Karnati HK, Li Y, Tweedie D, Mustapic M, Chawla S, Chowdhury K, Skene SS, Greig NH, Kapogiannis D, Foltynie T. Athauda D, et al. Among authors: gulyani s. JAMA Neurol. 2019 Apr 1;76(4):420-429. doi: 10.1001/jamaneurol.2018.4304. JAMA Neurol. 2019. PMID: 30640362 Free PMC article. Clinical Trial.

Cite

Share

3

Cite

Share

Association of Extracellular Vesicle Biomarkers With Alzheimer Disease in the Baltimore Longitudinal Study of Aging.

Kapogiannis D, Mustapic M, Shardell MD, Berkowitz ST, Diehl TC, Spangler RD, Tran J, Lazaropoulos MP, Chawla S, Gulyani S, Eitan E, An Y, Huang CW, Oh ES, Lyketsos CG, Resnick SM, Goetzl EJ, Ferrucci L. Kapogiannis D, et al. Among authors: gulyani s. JAMA Neurol. 2019 Nov 1;76(11):1340-1351. doi: 10.1001/jamaneurol.2019.2462. JAMA Neurol. 2019. PMID: 31305918 Free PMC article.

Cite

Share

4

Cite

Share

Sleep medicine pharmacotherapeutics overview: today, tomorrow, and the future (part 2: hypersomnia, parasomnia, and movement disorders).

Gulyani S, Salas RE, Gamaldo CE. Gulyani S, et al. Chest. 2013 Jan;143(1):242-251. doi: 10.1378/chest.12-0561. Chest. 2013. PMID: 23276849 Review.

Cite

Share

5

Cite

Share

Sleep medicine pharmacotherapeutics overview: today, tomorrow, and the future (Part 1: insomnia and circadian rhythm disorders).

Gulyani S, Salas RE, Gamaldo CE. Gulyani S, et al. Chest. 2012 Dec;142(6):1659-1668. doi: 10.1378/chest.12-0465. Chest. 2012. PMID: 23208340 Review.

Cite

Share

6

Cite

Share

In search of alternatives to dopaminergic ligands for the treatment of restless legs syndrome: iron, glutamate, and adenosine.

Ferré S, Earley C, Gulyani S, Garcia-Borreguero D. Ferré S, et al. Among authors: gulyani s. Sleep Med. 2017 Mar;31:86-92. doi: 10.1016/j.sleep.2016.08.019. Epub 2016 Nov 1. Sleep Med. 2017. PMID: 27899234 Review.

Cite

Share

7

Cite

Share

Evaluation of the effect comorbid Parkinson syndrome on normal pressure hydrocephalus assessment.

Davis A, Gulyani S, Manthripragada L, Luciano M, Moghekar A, Yasar S. Davis A, et al. Among authors: gulyani s. Clin Neurol Neurosurg. 2021 Aug;207:106810. doi: 10.1016/j.clineuro.2021.106810. Epub 2021 Jul 10. Clin Neurol Neurosurg. 2021. PMID: 34280677

Cite

Share

8

Cite

Share

Standardized regression-based clinical change score cutoffs for normal pressure hydrocephalus.

Davis A, Yasar S, Emerman I, Gulyani S, Khingelova K, Rao A, Manthripragada L, Luciano M, Moghekar A. Davis A, et al. Among authors: gulyani s. BMC Neurol. 2020 Apr 16;20(1):140. doi: 10.1186/s12883-020-01719-y. BMC Neurol. 2020. PMID: 32299370 Free PMC article.

Cite

Share

9

Cite

Share

Evaluating and Managing Sleep Disorders in the Parkinson's Disease Clinic.

Gulyani S, Salas R, Mari Z, Choi S, Mahajan A, Gamaldo C. Gulyani S, et al. Basal Ganglia. 2016 Aug;6(3):165-172. doi: 10.1016/j.baga.2016.05.001. Epub 2016 May 27. Basal Ganglia. 2016. PMID: 27818912 Free PMC article.

Cite

Share

10

Cite

Share

Effect of Patient-Specific Preanalytic Variables on CSF Aβ1-42 Concentrations Measured on an Automated Chemiluminescent Platform.

Darrow JA, Calabro A, Gannon S, Orusakwe A, Esquivel R, Traynham CJ, Rao A, Gulyani S, Khingelova K, Bandeen-Roche K, Albert M, Moghekar A. Darrow JA, et al. Among authors: gulyani s. J Appl Lab Med. 2021 Mar 1;6(2):397-408. doi: 10.1093/jalm/jfaa145. J Appl Lab Med. 2021. PMID: 33249440 Free PMC article.

Cite

Share